Filing Flows › Insulet (PODD) › R&D spending
Insulet (PODD) R&D spending by quarter
Insulet's R&D spending was $91.6M in Q3 2026 (third quarter 2026), +4% from Q2 2026. Over the last 7 quarters it ranged from $59.6M (Q1 2025) to $91.6M (Q3 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $91.6M | +4% | +19% |
| Q2 2026 | $88.1M | -2% | +20% |
| Q1 2026 | $89.7M | -1% | +51% |
| Q4 2025 | $90.9M | +18% | — |
| Q3 2025 | $77.2M | +5% | — |
| Q2 2025 | $73.4M | +23% | — |
| Q1 2025 | $59.6M | — | — |
Q3 2026 at a glance
Insulet, Q3 2026: revenue $842M (+19% year over year), operating margin 22.5%, net earnings $141M, operating cash flow $124M. The chart follows the revenue to costs, profit and cash.
Questions
What is Insulet's R&D spending?
Insulet's R&D spending was $91.6M in Q3 2026 (third quarter 2026), +4% from Q2 2026.
How has Insulet's R&D spending changed?
Over the last 7 quarters it ranged from $59.6M (Q1 2025) to $91.6M (Q3 2026).